French pharma major Sanofi's (Euronext: SAN) participation at the JP Morgan Healthcare Conference was marked by a comprehensive overview of its position in 2024 and its strategic vision for the future.
Sanofi’s chief executive Paul Hudson discussed the success of Dupixent (dupilumab)and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi. This achievement further underlines the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard, says pharma analytics company GlobalData.
Filippos Maniatis, healthcare analyst at GlobalData, commented: “Having Dupixent as the gold standard for AD, Sanofi has set a high benchmark for competitors within the space. Nevertheless, Sanofi’s CEO has underscored the need for increased competition, which is essential for a dynamic market, especially for AD.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze